{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-21-033010","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2021-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.501916+00:00","generated_at":"2026-06-29T00:27:09.151649+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cyclerion updates three CY6463 trials: CIAS Phase 1b enrolled, MELAS topline H1 2022, ADv screening","bullets":["First patients enrolled in Phase 1b study of CY6463 for cognitive impairment associated with schizophrenia (CIAS).","Phase 2a in MELAS remains enrolling; topline clinical results now expected in H1 2022.","Patient screening started in Phase 2a study of CY6463 for Alzheimer's disease with vascular pathology (ADv)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-21-033010","json":"https://secwatch.observer/filing/0001140361-21-033010.json","markdown":"https://secwatch.observer/filing/0001140361-21-033010.md","text":"https://secwatch.observer/filing/0001140361-21-033010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000114036121033010/0001140361-21-033010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000114036121033010/brhc10029438_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:27:09.151649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}